


## DOSING GUIDE

This guide refers to dosing of patients prescribed TECENTRIQ as per the EU Summary of Product Characteristics (SmPC). Treatment with TECENTRIQ must be initiated and supervised by physicians experienced in the treatment of cancer. For TECENTRIQ approved indications and full administration support see the SmPC.

### STANDARD TECENTRIQ ADMINISTRATION

- TECENTRIQ is for IV use (**not** IV push or bolus).
- Initial TECENTRIQ dose must be administered over 60 mins. If well tolerated, subsequent infusions may be administered over 30 mins.
- Dose reductions of TECENTRIQ are not recommended.
- If a planned dose of TECENTRIQ is missed, it should be administered as soon as possible.
- TECENTRIQ treatment is recommended until loss of clinical benefit or unmanageable toxicity.
- For pre-treatment care, pre-medication, lab tests, recording of vital signs and follow up, refer to local guidelines and individual SmPCs.

### IMMUNE-RELATED ADVERSE REACTIONS



### INFUSION-RELATED REACTIONS

The rate of infusion should be reduced or treatment should be interrupted in patients with Grade 1 or 2 infusion-related reactions. TECENTRIQ should be permanently discontinued in patients with Grade 3 or 4 infusion-related reactions.

Published by F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland | © December 2020 www.roche.com


All trademarks mentioned herein are protected by law. M-XX-00003869

### TNBC 1L

TECENTRIQ + NAB-PACLITAXEL

Treatment recommended until disease progression or unmanageable toxicity.

Q2W is the recommended dosing frequency for TECENTRIQ 840 mg.



28-day cycle one week without infusion

■ TECENTRIQ + NAB-PACLITAXEL  
■ NAB-PACLITAXEL

**DAYS 1 & 15**

TECENTRIQ 840 mg

30 minutes  
60 min for 1<sup>st</sup> infusion

→

**DAYS 1, 8, & 15**

NAB-PACLITAXEL 100 mg/m<sup>2</sup>


30 minutes



TECENTRIQ + CARBOPLATIN + ETOPOSIDE

Treatment recommended until disease progression or unmanageable toxicity.

Q3W is the recommended dosing frequency for TECENTRIQ combination therapies with four cycles and maintenance.



3-week interval  
Day 2 & 3 etoposide only

■ TECENTRIQ + CARBOPLATIN + ETOPOSIDE  
■ ETOPOSIDE

**INDUCTION | Q3W**

TECENTRIQ 1200 mg

30 minutes  
60 min for 1<sup>st</sup> infusion

→

**CARBOPLATIN**  
AUC 5 mg/ml/min<sup>a</sup>

30-60 minutes

\*Dose may vary as per local protocol and/or renal function

→

**ETOPOSIDE**  
100 mg/m<sup>2</sup>

60 minutes

same dose administered on Days 2 and 3 as well

**MAINTENANCE | Q3W**

TECENTRIQ 1200 mg


30 minutes

### NSCLC 1L

TECENTRIQ + AVASTIN + PACLITAXEL + CARBOPLATIN

Treatment recommended until disease progression or unmanageable toxicity.

Q3W is the recommended dosing frequency for TECENTRIQ combination therapies with four or six cycles.



3-week interval  
■ TECENTRIQ + AVASTIN + PACLITAXEL + CARBOPLATIN

**INDUCTION | Q3W**

TECENTRIQ 1200 mg

30 minutes  
60 min for 1<sup>st</sup> infusion

→

AVASTIN 15 mg/kg

30 minutes

→

PACLITAXEL 200 mg/m<sup>2</sup>

180 minutes

→

CARBOPLATIN AUC 6 mg/ml/min<sup>a</sup>

15 - 30 minutes

\*Dose may vary as per local protocol and/or renal function

**MAINTENANCE | Q3W**

TECENTRIQ 1200 mg

30 minutes

→

AVASTIN 15 mg/kg


30 minutes

### NSCLC 1L

TECENTRIQ + NAB-PACLITAXEL + CARBOPLATIN

Treatment recommended until disease progression or unmanageable toxicity.

Q3W is the recommended dosing frequency for TECENTRIQ combination therapies with four or six cycles.



21-day cycle  
■ TECENTRIQ + NAB-PACLITAXEL + CARBOPLATIN  
■ NAB-PACLITAXEL

**INDUCTION | Q3W**

Day 1 TECENTRIQ 1200 mg

30 minutes  
60 min for 1<sup>st</sup> infusion

→

**DAYS 1, 8 & 15**  
NAB-PACLITAXEL 100 mg/m<sup>2</sup>

30 minutes

→

Day 1 CARBOPLATIN AUC 6 mg/ml/min<sup>a</sup>

15 - 30 minutes

\*Dose may vary as per local protocol and/or renal function

**MAINTENANCE | Q3W**

TECENTRIQ 1200 mg

30 minutes

### NSCLC 2L

TECENTRIQ

Three flexible & convenient fixed dosing options.

4-week interval  
1680 mg IV (2x 840 mg IV)

3-week interval  
1200 mg IV

2-week interval  
840 mg IV

■ TECENTRIQ

**DOSING OPTIONS | Q2W, Q3W or Q4W**

TECENTRIQ

Until loss of clinical benefit or unmanageable toxicity.

30 minutes  
60 min for 1<sup>st</sup> infusion



TECENTRIQ

Three flexible & convenient fixed dosing options.

4-week interval  
1680 mg IV (2x 840 mg IV)

3-week interval  
1200 mg IV

2-week interval  
840 mg IV

■ TECENTRIQ

**DOSING OPTIONS | Q2W, Q3W or Q4W**

TECENTRIQ

Until loss of clinical benefit or unmanageable toxicity.

30 minutes  
60 min for 1<sup>st</sup> infusion

### HCC

TECENTRIQ + AVASTIN

Q3W is the recommended dosing frequency for TECENTRIQ combination therapies.

3-week interval  
■ TECENTRIQ + AVASTIN

**DOSING OPTIONS | Q3W**

TECENTRIQ 1200 mg

30 minutes  
60 min for 1<sup>st</sup> infusion

→

AVASTIN 15 mg/kg

30 minutes  
90 min for 1<sup>st</sup> infusion  
60 min for 2<sup>nd</sup> infusion